Rapid Pathogen Screening Announces New Vice President of Corporate Relations
SARASOTA, Fla., Oct. 19 /PRNewswire/ -- Rapid Pathogen Screening Inc., (RPS) announced the addition of William Ryan as Vice President of Corporate Relations. In this role, Bill will be responsible for developing the strategy and implementing the Group Purchasing Organizations and Integrated Delivery Networks' partnership programs. Most recently, Bill held a similar position in Celleration Inc.'s Corporate Accounts program. His 31 years of experience in the medical products industry includes positions responsible for developing Corporate Accounts Programs for start-up medical device companies as well as redirecting existing programs for larger organizations.
"Bill Ryan is a great addition to the RPS Sales leadership team. Bill has established many long standing positive relationships with key customers and has an excellent understanding of the medical device industry and specifically the GPO and IDN customer base," stated Thomas Orsini, CEO of Rapid Pathogen Screening. "With the RPS Adeno Detector(TM) receiving a CPT code effective January 1, 2008, coupled with the clinical and significant cost savings of the RPS device our focus has intensified toward the Group Purchasing Organizations and Integrated Networks. Bill's understanding and proven ability to develop partnerships with this customer base is invaluable to RPS."
About Rapid Pathogen Screening
Rapid Pathogen Screening, Inc. (RPS) develops point-of-care diagnostic devices for ocular diseases. The RPS Adeno Detector(TM), for detection of viral conjunctivitis, is the first in a family of tests.
The RPS Adeno Detector(TM) is the first true point of care test available for conjunctivitis. It provides a definitive result in 10 minutes and essentially makes available an accurate laboratory confirmation of adenoviral conjunctivitis at the time of the patient exam. The CLIA-waived RPS Adeno Detector(TM) can aid health care providers to make an accurate diagnosis, foster patient acceptance of more supportive therapies, identify contagious viral conjunctivitis, and limit the spread of disease while simultaneously reducing ocular antibiotic resistance and the cost of unnecessary antibiotics. The test is currently being used as an in-office test within many optometry and ophthalmology offices, military bases, and other centers for care across the United States. For more information, visit http://www.rps-tests.com.
kitsos@rps-tests.comhttp://www.rps-tests.com
CONTACT: Vicki Kitsos of Rapid Pathogen Screening, Inc., +1-941-556-1850,
kitsos@rps-tests.com
Web site: http://www.rps-tests.com/